Abstract: The present disclosure provides a fluorescence image registration method, the method includes: acquiring a fluorescence image of a biochip; selecting a preset local region of the fluorescence image; acquiring a position of a minimum value of a sum of brightness values of pixels in a first direction and a second direction, and obtaining pixel-level registration points; dividing the pixel-level registration points into non-defective pixels and defective pixels; if the fluorescence image meets the preset standard, correcting positions of the defective pixels according to positions of the non-defective pixels; acquiring a position of a center of gravity of image points of fluorescent molecules according to a center of gravity method; fitting straight lines in the first direction and the second direction respectively according to the position of the center of gravity; and acquiring boundary points of the fluorescence image and calculating the positions of the boundary points.

Abstract: Use of Anaerofustis stercorihominis in the prevention and/or treatment of metabolic diseases such as obesity, diabetes, atherosclerosis-related diseases, and cardiovascular diseases.

Abstract: The present invention relates to the field of biotechnology. A method and system of detecting fetal chromosomal abnormalities are disclosed.

Abstract: A method for generating a digital identity is provided, including: extracting a first preset number of short tandem repeat STRs and relevant information of each STR from whole genome data; generating a single STR digital code corresponding to each STR according to the relevant information of each STR, to obtain a plurality of single STR digital codes; performing sequence transformation on each single STR digital code with a preset rule, and generating a target STR digital code according to the single STR digital code after the sequence transformation; generating summary information of the target STR digital code, and determining the summary information as summary information of the STR to which the target STR digital code belongs; and determining the summary information of the STR as the generated digital identity.

Abstract: Provided are a polypeptide and nucleic acid for encoding the polypeptide, a nucleic-acid construct, an expression vector, and a host cell containing the nucleic acid, an antigen-presenting cell presenting the polypeptide on the surface of the cell, and immune effector cell thereof, a pharmaceutical composition containing the polypeptide, a vaccine containing the nucleic acid, the nucleic acid construct, the expression vector, the host cell, the antigen-presenting cell, and the immune effector cell, and an antibody recognizing the polypeptide. Also provided is a therapeutic method using the polypeptide, the nucleic acid, the pharmaceutical composition, the vaccine, and the antibody. Also provided are a diagnosis method and diagnosis apparatus for detecting the described polypeptide. Also provided is an application of the polypeptide in preparing a vaccine, a tumor diagnosis kit, or a pharmaceutical composition, and an application of the polypeptide or the nucleic acid as a test target in tumor diagnosis.

Abstract: The invention provides compositions and methods for sequencing nucleic acids and other applications. In sequencing by synthesis, unlabeled reversible terminators are incorporated by a polymerase in each cycle, then labeled after incorporation by binding to the reversible terminator a directly or indirectly labeled antibody or other affinity reagent.

Abstract: Provided are a nucleic acid sequencing method and a nucleic acid sequencing kit. The kit comprises a nucleic acid probe, a ligase, dNTP having a blocking group attached to a 3? end, a polymerase, a reagent 1 for excising the blocking group attached to the 3? end of the dNTP, and a reagent 2 for excising the remaining nucleotides on the nucleic acid probe that are not bound to a to-be-tested base group.

Abstract: The present disclosure proposes a modeling method and apparatus for diagnosing an ophthalmic disease based on artificial intelligence, and a storage medium. The modeling method includes: establishing a data collection of ophthalmic images and a data collection of non-image ophthalmic disease diagnosis questionnaires; training a first neural network model by employing the data collection of the ophthalmic images to obtain a first classification model; training a second classification model by employing the data collection of non-image ophthalmic disease diagnosis questionnaires; and merging the first classification model and the second classification model to obtain a target classification network model, in which, a test result outputted by the target classification network model is used as a diagnosis result of the ophthalmic disease.

Abstract: Disclosed is an antibody capable of specifically recognizing PCSK9 or an antigen-binding fragment thereof. The antibody comprises heavy chain variable region CDR1, CDR2, and CDR3 sequences shown in SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 or shown in amino acid sequences having at least 95% identity to SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3. The antibody can specifically bind to PCSK9 and inhibit the activity of PCSK9.

Abstract: Provided is a sequencing chip. The sequencing chip includes: a chip main body, nucleic acids, and a phosphonic acid polymer film. The chip main body includes a plurality of chip particles arranged in a same layer, the chip particles are obtained by cutting a chip matrix along cutting lines of a wafer layer, and the chip matrix includes: the wafer layer having the cutting lines uniformly distributed thereon; a first silicon oxide layer made of silicon oxide and formed on an upper surface of the wafer layer; and a transition metal oxide layer made of a transition metal oxide and formed on an upper surface of the first silicon oxide layer. The nucleic acids are fixed on the transition metal oxide layer; and the phosphonic acid polymer film is made of a polyphosphonic acid polymer and formed on an upper surface of the transition metal oxide layer.

Abstract: Provided in the present disclosure are a method for determining fetal nucleic acid concentration and a fetal genotyping method. According to the embodiments of the present disclosure, the method for determining cell-free fetal nucleic acid concentration includes: (1) acquiring sequencing data of a first nucleic acid sample of a pregnant woman and a reference genome sequence, the first nucleic acid sample of the pregnant woman containing cell-free fetal nucleic acids, and the sequencing data being composed of a plurality of sequencing reads; (2) selecting a predetermined region on the reference genome sequence and determining, based on the sequencing data of the first nucleic acid sample of the pregnant woman, mutation information in the predetermined region; and (3) determining the concentration of cell-free fetal nucleic acids corresponding to the predetermined region based on the mutation information in the predetermined region.

Abstract: Provided is an application of Butyribacter intestini in the treatment and prevention of obesity-related diseases. Also provided is a composition for the treatment and prevention of obesity and obesity-related diseases.

Abstract: Provided are a polypeptide and nucleic acid for encoding the polypeptide, a nucleic-acid construct, an expression vector, and a host cell containing the nucleic acid, an antigen-presenting cell presenting the polypeptide on the surface of the cell, and immune effector cell thereof, a pharmaceutical composition containing the polypeptide, a vaccine containing the nucleic acid, the nucleic acid construct, the expression vector, the host cell, the antigen-presenting cell, and the immune effector cell, and an antibody recognizing the polypeptide. Also provided is a therapeutic method using the polypeptide, the nucleic acid, the pharmaceutical composition, the vaccine, and the antibody. Also provided are a diagnosis method and diagnosis apparatus for detecting the described polypeptide. Also provided is an application of the polypeptide in preparing a vaccine, a tumor diagnosis kit, or a pharmaceutical composition, and an application of the polypeptide or the nucleic acid as a test target in tumor diagnosis.

Abstract: Provided are a polypeptide and nucleic acid for encoding the polypeptide, a nucleic-acid construct, an expression vector, and a host cell containing the nucleic acid, an antigen-presenting cell presenting the polypeptide on the surface of the cell, and immune effector cell thereof, a pharmaceutical composition containing the polypeptide, a vaccine containing the nucleic acid, the nucleic acid construct, the expression vector, the host cell, the antigen-presenting cell, and the immune effector cell, and an antibody recognizing the polypeptide. Also provided is a therapeutic method using the polypeptide, the nucleic acid, the pharmaceutical composition, the vaccine, and the antibody. Also provided are a diagnosis method and diagnosis apparatus for detecting the described polypeptide. Also provided is an application of the polypeptide in preparing a vaccine, a tumor diagnosis kit, or a pharmaceutical composition, and an application of the polypeptide or the nucleic acid as a test target in tumor diagnosis.

Abstract: Provided are a polypeptide and nucleic acid for encoding the polypeptide, a nucleic-acid construct, an expression vector, and a host cell containing the nucleic acid, an antigen-presenting cell presenting the polypeptide on the surface of the cell, and immune effector cell thereof, a pharmaceutical composition containing the polypeptide, a vaccine containing the nucleic acid, the nucleic acid construct, the expression vector, the host cell, the antigen-presenting cell, and the immune effector cell, and an antibody recognizing the polypeptide. Also provided is a therapeutic method using the polypeptide, the nucleic acid, the pharmaceutical composition, the vaccine, and the antibody. Also provided are a diagnosis method and diagnosis apparatus for detecting the described polypeptide. Also provided is an application of the polypeptide in preparing a vaccine, a tumor diagnosis kit, or a pharmaceutical composition, and an application of the polypeptide or the nucleic acid as a test target in tumor diagnosis.

Abstract: Provided are a composition and the uses thereof. Said composition comprises Megamonas funimormis and/or a metabolite thereof, as well as Anaerofustis stercorihominis and/or a metabolite thereof. Said composition can efficiently treat and prevent inflammation, specifically ulcerative colitis, and related diseases thereof by using a combination of Megamonas funimormis and Anaerofustis stercorihominis, and is safe, efficient, exhibits low toxicity and does not easily produce resistance.

Abstract: Provided is a use of Butyribacter intestini in preventing and/or treating inflammation-related diseases. Specifically, in the present disclosure, it was firstly discovered that Butyribacter intestini has the function of preventing and/or treating inflammation-related diseases (for example, inflammatory bowel disease, such as ulcerative colitis, gastritis, and common enteritis; and rheumatoid arthritis).

Abstract: The present invention discloses an application of Bacteroides cellulosilyticus in preparing a preparation for preventing and/or treating lipid metabolism related diseases, such as atherosclerosis related diseases, cardiovascular diseases and obesity.

Abstract: Provided is a method for isolating exosomal DNA, the method comprising: (i) providing a sample, wherein the sample comprises a blood sample from peripheral blood of a pregnant woman; and (ii) subjecting the sample to isolating, thus obtaining the exosomal DNA. Also provided are a method for detecting a blood sample, a method for constructing a sequencing library on a blood sample, a method for high-throughput sequencing an exosomal DNA sequencing library, a method for non-invasive prenatal gene detection, a device for non-invasive prenatal gene detection, and a kit for detecting a blood sample and use thereof.

Abstract: Provided are a chip matrix, a sequencing chip, and a manufacturing method thereof. The chip matrix includes: a wafer layer (111), the wafer layer (111) having cutting lines that are evenly distributed thereon; a first silicon oxide layer (112), the first silicon oxide layer (112) being made of silicon oxide and formed on an upper surface of the wafer layer (111); a transition metal oxide layer (113), the transition metal oxide layer (113) being made of transition metal oxide and formed on an upper surface of the first silicon oxide layer (112). The chip matrix has characteristics such as resistances against high temperature, high humidity and other harsh environments. Meanwhile, by changing pH, surfactant and other components of a solution containing sequences to be sequenced, a surface functional region of the chip matrix can specifically adsorb a sequence to be sequenced.